Movatterモバイル変換

[0]ホーム
URL:

GB1183403A - Antitussive Medicament with Prolonged Effect - Google Patents

Antitussive Medicament with Prolonged Effect

Info

Publication number
GB1183403A
GB1183403AGB9794/67AGB979467AGB1183403AGB 1183403 AGB1183403 AGB 1183403AGB 9794/67 AGB9794/67 AGB 9794/67AGB 979467 AGB979467 AGB 979467AGB 1183403 AGB1183403 AGB 1183403A
Authority
GB
United Kingdom
Prior art keywords
antitussive
base
weight
medicament
noscapine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB9794/67A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mead Johnson and Co LLC
Original Assignee
Mead Johnson and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mead Johnson and Co LLCfiledCriticalMead Johnson and Co LLC
Publication of GB1183403ApublicationCriticalpatent/GB1183403A/en
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

1,183,403. Antitussive medicament. MEAD JOHNSON & CO. 1 March, 1967 [18 March, 1966], No. 9794/67. Heading A5B. [Also in Division C3] Antitussive compositions having prolonged effect contain in each dosage unit an effective amount of at least one of the complexes of a sulphated polysaccharide selected from the group of carrageenans and an antitussive base selected from the opium alkaloids and synthetic derivatives and analogues thereof, said complex being formed by contacting a watersoluble acid addition salt of said base with an aqueous solution containing from 1 to 10 parts by weight of sulphated polysaccharide per part by weight of said base at a temperature of 40-60‹C. The antitussive base may be morphine, codeine, noscapine, pholcodine, ethylmorphine, diacetylmorphine, dihydromorphine, dihydrocodeinone or dextromethorphan, the complex containing 9 to 50% by weight of the base. The compositions may be administered orally in the form of liquids, compressed tablets and gelatin capsules. A preferred composition contains carrageenan complexes of codeine and noscapine.
GB9794/67A1966-03-181967-03-01Antitussive Medicament with Prolonged EffectExpiredGB1183403A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
FR54024AFR5227M (en)1966-03-181966-03-18

Publications (1)

Publication NumberPublication Date
GB1183403Atrue GB1183403A (en)1970-03-04

Family

ID=8604122

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GB9794/67AExpiredGB1183403A (en)1966-03-181967-03-01Antitussive Medicament with Prolonged Effect

Country Status (6)

CountryLink
AT (1)AT279802B (en)
BE (1)BE695604A (en)
DK (1)DK115144B (en)
FR (1)FR5227M (en)
GB (1)GB1183403A (en)
NL (1)NL6704037A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0091409A1 (en)*1982-03-121983-10-12KabiVitrum ABPharmaceutical compositions containing carrageen
EP0233932A4 (en)*1985-08-161988-04-26Univ New York ANTICONVULSIVE COMPOSITIONS AND METHODS RELATING thereto.
US4898860A (en)*1985-08-161990-02-06New York UniversityAnticonvulsant composition and method
FR2640137A1 (en)*1988-12-081990-06-15Texinfine Sa SYSTEMS CONVEYING LIPOPHILIC ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING SAME
EP0454044A3 (en)*1990-04-251993-01-13Hoechst AktiengesellschaftPharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
WO1999021586A3 (en)*1997-10-291999-07-08Eurand IntComplex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions
FR2906687A1 (en)*2006-10-102008-04-11Pierre CallejaSubstrate for conservation and distribution of an active ingredient for aquatic animals, comprises an active ingredient, a hydrocolloid substance to inflate in contact with water, a palatable base, and a compressed metal base
US7939103B2 (en)2004-03-192011-05-10Capsulution Pharma AgMethod for producing core-shell (CS) particles and microcapsules using porous templates, CS particles and microcapsules, and the use thereof
US8092836B2 (en)1998-03-192012-01-10Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4762709A (en)*1983-09-161988-08-09Pennwalt CorporationLiquid prolonged release pharmaceutical formulations containing ionic constituents
AU565487B2 (en)*1983-09-161987-09-17Fisons CorporationLiquid prolonged release pharmaceutical formulations containing ionic constituents

Cited By (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0091409A1 (en)*1982-03-121983-10-12KabiVitrum ABPharmaceutical compositions containing carrageen
US4693997A (en)*1982-03-121987-09-15Kabivitrum AbNovel pharmaceutical composition
EP0233932A4 (en)*1985-08-161988-04-26Univ New York ANTICONVULSIVE COMPOSITIONS AND METHODS RELATING thereto.
US4898860A (en)*1985-08-161990-02-06New York UniversityAnticonvulsant composition and method
FR2640137A1 (en)*1988-12-081990-06-15Texinfine Sa SYSTEMS CONVEYING LIPOPHILIC ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING SAME
US5700459A (en)*1990-04-251997-12-23Hoechst AktiengesellschaftPharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active agent
EP0454044A3 (en)*1990-04-251993-01-13Hoechst AktiengesellschaftPharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
WO1999021586A3 (en)*1997-10-291999-07-08Eurand IntComplex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions
US6355272B1 (en)1997-10-292002-03-12Eurand International S.P.A.Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions
US8092836B2 (en)1998-03-192012-01-10Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US8168226B2 (en)1998-03-192012-05-01Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US7939103B2 (en)2004-03-192011-05-10Capsulution Pharma AgMethod for producing core-shell (CS) particles and microcapsules using porous templates, CS particles and microcapsules, and the use thereof
FR2906687A1 (en)*2006-10-102008-04-11Pierre CallejaSubstrate for conservation and distribution of an active ingredient for aquatic animals, comprises an active ingredient, a hydrocolloid substance to inflate in contact with water, a palatable base, and a compressed metal base

Also Published As

Publication numberPublication date
BE695604A (en)1967-09-18
NL6704037A (en)1967-09-19
FR5227M (en)1967-08-14
DK115144B (en)1969-09-08
AT279802B (en)1970-03-25

Similar Documents

PublicationPublication DateTitle
GB1390772A (en)Oral narcotic composition
GB1183403A (en)Antitussive Medicament with Prolonged Effect
IE771403L (en)Injection solutions
KR890009376A (en) Spray dried ibuprofen
IE781163L (en)Sustained release of veterinary medicaments
GB1517480A (en)Opiate analgesic formulation with a low potential for abuse
GB1353815A (en)Analgetic composition
CA2190943A1 (en)Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
DE814775T1 (en) METHOD AND KIT FOR PREVENTING ERECTILE DYSFUNCTION
GB1378348A (en)Orally administered drug composition for therapy in the treatment of narcotic drug addiction
NL172149B (en) PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH A LOCAL ANESTHETIC EFFECT CONTAINING A DIALKYLAMINO-2 ', 6'-BUTYROXYLIDIDE AND / OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREFORE PREPARED FOR THESE PREPARED IN THESE PREPARATION OF DIALKYLAMINO-2 ', 6'-BUTYROXILIDES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS.
ES320356A1 (en) PROCEDURE FOR THE PREPARATION OF EDIBLE MEDICINAL PILLS
IL40457A0 (en)New esters and salts of oburnamine type alkaloids,their preparation and pharmaceutical compositions containing them
US3456051A (en)Soft gelatin sheet for soft gelatin capsule
HartmannAmitriptyline and imipramine: effects on human sleep.
GB1186990A (en)Sustained Release Tablet Coating.
IL49668A0 (en)Stable solutions of ergot alkaloids,their preparation and pharmaceutical compositions comprising them
GB769517A (en)Analgesic compositions
IL35490A0 (en)New penicillanic acid derivatives,their preparation and pharmaceutical compositions containing them
GB1442159A (en)Pharmaceutical compositions containing paracetamol
IL46864A0 (en)New pyrimido(1,2-a)quinoline derivatives,their preparation and pharmaceutical compositions containing them
GB1547562A (en)Guns eg for use in the administration of drugs or medicines to animals
GB1300419A (en)New morphinone derivatives and their preparation
IE34648L (en)Pharmaceutical composition containing garcinia acid
GB791644A (en)Barbiturate pharmaceutical preparations

Legal Events

DateCodeTitleDescription
PSPatent sealed
PLNPPatent lapsed through nonpayment of renewal fees
[8]ページ先頭
©2009-2025 Movatter.jp